Nobody gave it data. Nobody gave it tools. Nobody wrote a line of code. 12 hours later, the AI system it delivered beat a system published in the main Nature journal on public benchmarks.
Rare disease diagnosis is one of the hardest problems in medicine: more than 7,000 rare diseases are known worldwide, each one vanishingly rare, and patients typically spend years bouncing between hospitals before a diagnosis is confirmed. In 2026, a human research team published their multi-agent AI diagnostic system in the main Nature journal.
A multi-agent rare disease diagnostic system published in Nature, Vol 651 (2026).
One sentence of task description. Zero data. Zero human intervention. All of it done by the AI itself.
Every act below is a process that actually took place during this run.
It started from zero records. It searched public medical databases online, found confirmed-case repositories published by global rare disease research consortia, extracted each patient's symptom codes, causal genes and final diagnosis one by one, then filtered out duplicates and low-quality samples.
Cases alone weren't enough. It downloaded the entire international-standard Human Phenotype Ontology — a vast network describing the hierarchical relationships between every clinical symptom — then wired in disease-to-symptom tables and gene-to-disease mappings to assemble a knowledge foundation it could reason over.
Knowledge sitting on a shelf isn't usable — you need decent instruments to read it. For instance, it built itself a set of "diagnostic instruments": starting from symptoms, it follows three lines of evidence in parallel to find candidate diseases, scores every candidate on how well it fits, then trains a ranker to fuse those scores into a confidence ranking. It built more than one toolset like this, and every one of them was torn down and rewritten many times over — each version had to be measured to see whether it genuinely improved, and if it didn't, it was rolled back.
Data, knowledge base and tools were assembled into a complete runtime environment — a workbench where an AI doctor can check and re-check its own work: retrieve the evidence first, verify it against authoritative descriptions, and only then commit to a conclusion. It then ran that pipeline end to end, validated it, and optimized it.
It built and optimized its own training set, launched several runs with different hyperparameters in parallel, and then picked the best performer on a held-out set it had reserved for itself. At no point did anyone tell it what configuration to use, how long to train, or which one to pick.
Not a single AI model, but a complete diagnostic system — an AI doctor that knows how to use tools, plus every piece of knowledge and instrumentation it needs to work. The whole thing can be packaged up, taken away, and run and evaluated offline.
Standard benchmarks: 556 real cases it had never seen. The evaluation was re-run by a third party in an isolated environment — the AI could not see the questions and received no feedback. The metric is standard Recall@K — the share of cases where the correct diagnosis appears among the system's top K candidates.
In this run, all Apodex Discovery received was one sentence of task description. It found the data itself from public sources, built the system itself, and the packaged deliverable runs the entire evaluation offline. In other words — from start to finish, we never touched a single piece of private data.
Spell out what problem you want solved and what counts as getting it right. Data collection, knowledge base, tools and training are all handled by the system itself. Your data plays no part in training.
A lightweight model plus every piece of knowledge and instrumentation it needs to work, packaged up and deployed on your own servers. Not an API call — an asset you own.
Inference needs no internet connection at any point. Patient records, samples, molecular structures, experiment logs — this data moves only inside your own server room, and never a step beyond it.
What was actually proven is this: Apodex Discovery can already run an entire research pipeline on its own — setting the approach, finding the data, building the tools, designing the experiments, training the models, validating itself, and delivering the result. Apodex Discovery is now being applied to biology, clinical medicine, chemistry and materials. And all you ever have to give it is one sentence.
All figures come from the complete trace log of a single real run and third-party evaluation results. Human state of the art references the values publicly reported in DeepRare (Nature, Vol 651, 2026).